Antibody-based therapeutics are promising for treating central nervous system (CNS) diseases; however, brain delivery is severely restricted by the blood–brain barrier (BBB). Intranasal administration has gained attention as a noninvasive route proposed to reduce the impact of the BBB; however, the efficiency of delivering large biomolecules, such as antibodies, remains insufficiently characterized. This study aimed to investigate whether cell-penetrating peptides (CPPs) could increase detectable IgG levels in the cerebrospinal fluid (CSF) following intranasal administration in mice. Rabbit IgG was intranasally administered to ICR mice, either alone or in combination with CPPs (R9, Penetratin, or L17E). IgG levels in the CSF and serum were quantified by ELISA, and both time-course and dose-dependent effects were analyzed. IgG alone was not detected in the CSF, whereas serum IgG levels increased dose-dependently. Co-administration of Penetratin or L17E resulted in detectable CSF IgG levels, with L17E exceeding Penetratin. By contrast, no delivery was observed in the R9 group. Serum IgG levels also increased in the Penetratin and L17E groups. Time-course analysis with L17E showed that CSF IgG reached its highest measured level at 24 h and declined thereafter, whereas serum IgG reached higher levels at earlier time points and remained relatively stable. Dose–response analysis revealed linear increases in serum IgG, while CSF IgG levels depended on the concentration of L17E. These findings indicate that co-administration with amphipathic CPPs, particularly L17E, enables detectable IgG delivery to the CSF following intranasal administration in mice, although the underlying mechanisms and therapeutic relevance remain to be clarified.
扫码关注我们
求助内容:
应助结果提醒方式:
